InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
InspireMD (NSPR), developer of the CGuard™ Embolic Prevention Stent System for Carotid Artery Disease and stroke prevention, has scheduled its Third Quarter 2024 financial results announcement for Tuesday, November 12th, 2024, before market open. The company will host a conference call and webcast at 8:30 AM EDT to discuss financial results and provide corporate updates. The call will be accessible via toll-free (1-800-225-9448) and international (1-203-518-9708) numbers, with conference ID: IMD3Q24. A webcast will be available through the company's website.
InspireMD (NSPR), sviluppatore del CGuard™ Embolic Prevention Stent System per la malattia dell'arteria carotidea e la prevenzione degli ictus, ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per martedì 12 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 8:30 AM EDT per discutere i risultati finanziari e fornire aggiornamenti aziendali. La chiamata sarà accessibile tramite numero verde (1-800-225-9448) e numero internazionale (1-203-518-9708), con ID conferenza: IMD3Q24. Una trasmissione in diretta sarà disponibile attraverso il sito web dell'azienda.
InspireMD (NSPR), desarrollador del CGuard™ Embolic Prevention Stent System para la enfermedad de la arteria carótida y la prevención de accidentes cerebrovasculares, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024, antes de la apertura del mercado. La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo a las 8:30 AM EDT para discutir los resultados financieros y proporcionar actualizaciones corporativas. La llamada será accesible a través del número gratuito (1-800-225-9448) y el número internacional (1-203-518-9708), con ID de conferencia: IMD3Q24. Se dispondrá de una transmisión en vivo en el sitio web de la empresa.
InspireMD (NSPR)는 경동맥 질환 및 뇌졸중 예방을 위한 CGuard™ Embolic Prevention Stent System의 개발업체로, 2024년 3분기 재무 결과 발표를 2024년 11월 12일 화요일 시장 개장 전에 예정하고 있습니다. 회사는 8:30 AM EDT에 재무 결과 및 기업 업데이트를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다. 전화는 무료번호(1-800-225-9448) 및 국제번호(1-203-518-9708)를 통해 접속할 수 있으며, 회의 ID는 IMD3Q24입니다. 회사 웹사이트를 통해 웹캐스트가 제공될 예정입니다.
InspireMD (NSPR), développeur du CGuard™ Embolic Prevention Stent System pour la maladie de l'artère carotide et la prévention des AVC, a programmé l'annonce de ses résultats financiers du troisième trimestre 2024 pour le mardi 12 novembre 2024, avant l'ouverture du marché. La société organisera une conférence téléphonique et un webinaire à 8h30 EDT pour discuter des résultats financiers et fournir des mises à jour sur l'entreprise. L'appel sera accessible par le numéro sans frais (1-800-225-9448) et par le numéro international (1-203-518-9708), avec l'ID de conférence : IMD3Q24. Un webinaire sera disponible sur le site web de l'entreprise.
InspireMD (NSPR), Entwickler des CGuard™ Embolic Prevention Stent System zur Behandlung von Carotis-Arterienerkrankungen und zur Schlaganfallprävention, hat die Ankündigung seiner Finanzergebnisse für das dritte Quartal 2024 für Dienstag, den 12. November 2024, vor Markteröffnung geplant. Das Unternehmen wird um 8:30 Uhr EDT eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse zu erörtern und Unternehmensaktualisierungen bereitzustellen. Der Anruf ist kostenlos unter der Nummer (1-800-225-9448) sowie international unter der Nummer (1-203-518-9708) erreichbar, mit der Konferenz-ID: IMD3Q24. Ein Webcast wird über die Unternehmenswebsite verfügbar sein.
- None.
- None.
-Conference call and webcast to be held at 8:30 a.m. EDT-
TEL AVIV, Israel and MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2024 financial results on Tuesday, November 12th, 2024, before the financial markets open.
Management will host a conference call and webcast with the investment community at
8:30 am (EDT) that same day to review financial results and provide an update on corporate developments.
Title: | InspireMD Third Quarter 2024 Financial Results and Corporate Update Conference Call and Webcast |
| Date: | Tuesday, November 12th, 2024 |
| Time: | 8:30 a.m. ET |
| Conference Call Details: | Toll-Free: 1-800-225-9448 International: 1-203-518-9708 Conference ID: IMD3Q24 |
| The conference call will be webcast live from the Company’s website and will be available via the following links: | |
| Webcast: | Webcast link – click here https://www.inspiremd.com/en/investors/investor-relations/ |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. For example, the company is using forward looking statements when it discusses the expansion of its portfolio and potential indications and that the CGuard Carotid stent provides a foundational advantage for improved patient outcomes and prevention of stroke. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
FAQ
When will InspireMD (NSPR) report Q3 2024 earnings?
How can I join InspireMD's (NSPR) Q3 2024 earnings call?
What time is InspireMD's (NSPR) Q3 2024 earnings call?
